To the best of our knowledge, this study is the first to demonstrate the value of tumor 18F-fluorodeoxyglucose metabolism for the long-term prognosis of DRFS and OS in patients with ER-positive, HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.